{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T09:17:20Z","timestamp":1720689440994},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.3816\/clm.2008.s.002","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T01:34:50Z","timestamp":1221528890000},"page":"S75-S81","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S3","title":["Optimizing Treatment with Bcr-Abl Tyrosine Kinase Inhibitors in Philadelphia Chromosome\u2014Positive Chronic Myeloid Leukemia: Focus on Dosing Schedules"],"prefix":"10.3816","volume":"8","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2008.s.002_bib1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1 suppl 1","key":"10.3816\/CLM.2008.s.002_bib3","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminhematol.2006.12.007","article-title":"The biology of chronic myelogenous leukemia: implications for imatinib therapy. S","volume":"44","author":"Alvarez","year":"2007","journal-title":"emin Hematol"},{"key":"10.3816\/CLM.2008.s.002_bib4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia: diagnosis and treatment","volume":"81","author":"Quint\u00e1s-Cardama","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLM.2008.s.002_bib5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CLM.2008.s.002_bib6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1517\/14712598.6.10.1011","article-title":"Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia","volume":"6","author":"Piccaluga","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.3816\/CLM.2008.s.002_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2008.s.002_bib8","first-page":"139","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by ckit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3816\/CLM.2008.s.002_bib9","series-title":"Gleevec\u00ae (imatinib) [package insert]","year":"2007"},{"key":"10.3816\/CLM.2008.s.002_bib10","series-title":"Sprycel\u00ae (dasatinib) [package insert]","year":"2007"},{"key":"10.3816\/CLM.2008.s.002_bib11","series-title":"Tasigna\u00ae (nilotinib) [package insert]","year":"2007"},{"key":"10.3816\/CLM.2008.s.002_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.3816\/CLM.2008.s.002_bib13","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/1078-0432.CCR-05-0622","article-title":"Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src\/Abl inhibitors are compatible with imatinib","volume":"11","author":"O'Hare","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.002_bib14","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2008.s.002_bib15","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin- 4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.3816\/CLM.2008.s.002_bib16","doi-asserted-by":"crossref","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","article-title":"Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells","volume":"65","author":"Nam","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2008.s.002_bib17","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1073\/pnas.0511292103","article-title":"An efficient rapid system for profiling the cellular activities of molecular libraries","volume":"103","author":"Melnick","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2008.s.002_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [published erratum in: Cancer Cell 2005; 7:399]","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2008.s.002_bib19","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.002_bib20","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib21","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib22","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.002_bib23","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome\u2013 positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib24","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.002_bib25","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome [published erratum in: N Engl J Med 2001; 345:232]","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.002_bib26","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","article-title":"Result of high-dose imatinib mesylate in patients with Philadelphia chromosome\u2013positive chronic myeloid leukemia after failure of interferon-alpha","volume":"102","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib29","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","article-title":"Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses","volume":"102","author":"Marin","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib30","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.002_bib31","first-page":"534","article-title":"New tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"90","author":"Martinelli","year":"2005","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.002_bib32","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome\u2013positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib33","doi-asserted-by":"crossref","first-page":"608a","DOI":"10.1182\/blood.V108.11.2143.2143","article-title":"High-dose (HD) imatinib provides better responses in patients with untreated early chronic phase (CP) CML","volume":"108","author":"Aoki","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib34","doi-asserted-by":"crossref","first-page":"609a","DOI":"10.1182\/blood.V108.11.2149.2149","article-title":"Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT Trial Study Group","volume":"108","author":"Cortes","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib35","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood.V108.11.2775.2775","volume":"108","author":"Rosti","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1600-0609.2006.00649.x","article-title":"Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia","volume":"76","author":"Moore","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2008.s.002_bib37","unstructured":"Hochhaus A, Kim DW, Rousselot P, et al. Dasatinib dose and schedule optimization in chronic-phase CML resistant or intolerant to imatinib: results from a randomized phase-III trial (CA180034). Presented at: 12th Congress of the European Hematology Association; June 7\u201310, 2007; Vienna, Austria. Abstract 359."},{"key":"10.3816\/CLM.2008.s.002_bib38","doi-asserted-by":"crossref","first-page":"613a","DOI":"10.1182\/blood.V108.11.2160.2160","article-title":"Dasatinib (Sprycel\u00ae) in patients (pts) with chronic myelogenous leukemia in accelerated phase (APCML) that is imatinib-resistant (im-r) or -intolerant (im-i): updated results of the CA180-005 START-A phase II study","volume":"108","author":"Cortes","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib39","doi-asserted-by":"crossref","first-page":"224a","DOI":"10.1182\/blood.V108.11.745.745","article-title":"Dasatinib (Sprycel\u00ae) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (im-r) or -intolerant (im-i)","volume":"108","author":"Martinelli","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLM.2008.s.002_bib40","first-page":"128","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic-phase CML with resistance or intolerance to imatinib: updated results of the CA180013 (START-C) trial","volume":"92","author":"Guilhot","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.002_bib41","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or highdose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLM.2008.s.002_bib42","first-page":"9","article-title":"Dasatinib induces rapid and durable responses in patients with Ph+ ALL resistant or intolerant to imatinib: updated results from CA180015 (START-L) trial","volume":"92","author":"Ottmann","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.002_bib43","unstructured":"Dombret H, Ottmann OG, Goh Y, et al. Dasatinib 140 mg QD vs 70 mg bid in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: results from a randomized, phase-III trial (CA180035). Presented at: 12th Congress of the European Hematology Association; June 7\u201310, 2007; Vienna, Austria. Abstract 859."},{"key":"10.3816\/CLM.2008.s.002_bib44","doi-asserted-by":"crossref","first-page":"614a","DOI":"10.1182\/blood.V108.11.2166.2166","article-title":"Potent transient inhibition of BCR-ABL by dasatinib leads to complete cytogenetic remissions in patients with chronic myeloid leukemia: implications for patient management and drug development","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib45","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinibresistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.002_bib46","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","article-title":"Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)","volume":"108","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib47","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl- N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib48","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.002_bib49","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.002_bib50","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.002_bib51","first-page":"367s","article-title":"A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed\/refractory Ph+ acute lymphoblastic leukemia (ALL)","volume":"25","author":"Larson","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T08:38:21Z","timestamp":1588927101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011702682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":51,"alternative-id":["S1557919011702682"],"URL":"https:\/\/doi.org\/10.3816\/clm.2008.s.002","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}